Skip to content

Study · Not a test of the peptide alone · 2025

1 result

REG3A promotes gemcitabine resistance in pancreatic cancer via the GPR54/ARRB2/ERK1/2 ligand-directed signaling pathway.

Liu J, Li S, Zhou H, Wang M, Zhang C, Tian C, Xu Y, Wang M, Li X, Li Q, Xiang M

Biochemical pharmacology9 Sept 2025Cited by 2 (Europe PMC)

PMID40935160 (opens in a new tab)DOI10.1016/j.bcp.2025.117322 (opens in a new tab)PepBankPUB-40935160
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 01LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Mechanism

    In pancreatic cancer models, the GPR54 agonist KP10 together with REG3A synergistically enhanced gemcitabine resistance.

    In plain wordsIn pancreatic cancer lab models, KP10 together with REG3A made the cancer more resistant to gemcitabine.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseGemcitabine resistance with KP10 plus REG3A
    Study

    n: not reported in source

    Pancreatic cancer models (cell or animal model not specified in this sentence)
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Moreover, the GPR54 agonist KP10 synergistically enhanced gemcitabine resistance in conjunction with REG3A

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.